The myelin oligodendrocyte glycoprotein (MOG), a minor component of the compact myelin sheath, is now emerging as a target autoantigen in patients with specific clinical neurological dysfunction collectively termed as MOG-antibody disease, which does not meet the typical criteria for MS or other known neuroinflammatory conditions (4). The gene discussed is MOG; the disease is myeloid sarcoma.